Monday December 16, the Toulouse University Hospital presented BIOFACEalongside the project partners and in the presence of Marianne Peyrot, academic region director for research and innovation.
BIOFACE has risen to the rank of program of excellence as part of the health component of France 2030 “Health Innovation 2030”. It benefits from funding of €4.395 million from the national research agency.
Pr Agnès Dupret-Bories, leader of the BIOFACE project
Led by Professor Agnès Dupret-Bories, this project aims to modify the treatment of patients undergoing oral cancer surgery and improve their quality of life, thanks to a surgical process for reconstructing facial bones which relies on biomaterials. This method will – among other things – minimize the risks of failure encountered during bone grafts.
While also reducing the animal experimentation necessary for pre-clinical studies, BIOFACE will make it possible to identify the risk factors associated with oral cavity cancers which are on the increase.
The first clinical trials in humans are planned for 2029.
Cancerology at Toulouse University Hospital
In terms of cancerology, the Toulouse University Hospital care offering is based on an organization around three hospital sites labeled “University Cancer Institute – Toulouse”: IUCT-Rangueil-Larrey, IUCT-Purpan and IUCT-Oncopole.
These sites work in a complementary manner, without duplication, and promote a multidisciplinary and coordinated approach to cancer, integrating both care and research.
Among these sites, the IUCT-Oncopole stands out for its exclusive vocation: it is entirely dedicated to the fight against cancer. This unique site brings together, on the same campus, the expertise of the Toulouse University Hospital teams and those of the Oncopole Claudius Regaud (OCR).
In western Occitanie, the Toulouse University Hospital carries out 39% of hospitalizations linked to cancer treatment, thus representing the largest share of activity in this area. Cancer treatment constitutes up to 25% of the CHU’s overall activity.
Oncology research occupies a central place in the CHU’s strategy. With 1,244 patient inclusions in clinical trials and 456 active research projects, Toulouse University Hospital confirms its commitment to advancing knowledge and treatments to better meet the needs of patients.
Agnès Dupret-Bories and her partners aim to develop a technique specifically dedicated to the most complex cases in terms of reconstruction: cancers affecting the mouth.
View the press kit below:
